511 related articles for article (PubMed ID: 28248961)
1. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
[TBL] [Abstract][Full Text] [Related]
3. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
4. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
[TBL] [Abstract][Full Text] [Related]
6. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients.
Navaneethan SD; Palmer SC; Vecchio M; Craig JC; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2011 Feb; (2):CD006023. PubMed ID: 21328279
[TBL] [Abstract][Full Text] [Related]
7. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
[TBL] [Abstract][Full Text] [Related]
8. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
[TBL] [Abstract][Full Text] [Related]
10. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet versus standard treatment for chronic kidney disease: a protocol for a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Mustafa RA; Guyatt GH; Thabane L
Syst Rev; 2016 Jan; 5():2. PubMed ID: 26729302
[TBL] [Abstract][Full Text] [Related]
12. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Zhao L; Liu A; Xu G
Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Zhou T; Li H; Xie W; Lin Z
Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
[TBL] [Abstract][Full Text] [Related]
15. Interventions for bone disease in children with chronic kidney disease.
Geary DF; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2010 Jan; (1):CD008327. PubMed ID: 20091666
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Zhang C; Wen J; Li Z; Fan J
BMC Nephrol; 2013 Oct; 14():226. PubMed ID: 24134531
[TBL] [Abstract][Full Text] [Related]
17. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
18. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
[TBL] [Abstract][Full Text] [Related]
19. PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Yaguchi A; Tatemichi S; Takeda H; Kobayashi M
PLoS One; 2017; 12(7):e0180430. PubMed ID: 28704404
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
